Distributed Bio Inc and Good Therapeutics, Inc. Announce Multi-Target Collaboration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Distributed Bio, the global leader in computational optimization of fully human monoclonal antibody libraries, today announced a multi-target partnership with Good Therapeutics Inc. Distributed Bio will use its proprietary SuperHuman antibody library platform to discover therapeutic ready pre-optimized antibodies against multiple Good targets. Good will have the right to develop and commercialize therapeutic programs resulting from the collaboration.

"Rapid discovery of therapeutic ready antibodies is critical to our research plan and the success of the company," stated John Mulligan, Ph.D., CEO of Good. "That’s why after evaluating the many options available for novel antibody discovery, it was clear Distributed Bio and the SuperHuman platform provides Good with the fastest path to novel therapeutics. The speed and efficacy of Distributed Bio’s discovery services will make them a key contributor our business plan."

"We’re delighted to be working with Good and John," said Jacob Glanville Ph.D., Co-founder & CSO, Distributed Bio. "Both companies bring innovative platforms and creative thinking to therapeutics discovery. Working together we can pursue antibody therapeutics against targets and modalities that were unthinkable only 1 or 2 years ago."

About Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.

About Distributed Bio

Distributed Bio is a computational immunoengineering biotechnology group, self-funded by licensing a stack of technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.

From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, sanger sequence, and functional assay without requiring large datacenter investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman antibody discovery platform. SuperHuman overcomes many of the limitation of other monoclonal generation technologies with an unprecedented diversity and developable fitness that has resulted in a unique engineering opportunity: a library that generates over 5000 unique hits against every antigen tested, including hundreds of unique picomolar binders against such challenging targets as PD1 and GHR. Given the number of hits, this library can be panned under unprecedented aggressive conditions, recovering hundreds of subnanomolar binders in under a week, recovering saturating coverage of hits against every epitope, and isolating multi-species cross-reactive members against target homologs without additional engineering.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005014/en/